<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483963</url>
  </required_header>
  <id_info>
    <org_study_id>AUX-CC-870</org_study_id>
    <nct_id>NCT01483963</nct_id>
  </id_info>
  <brief_title>AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder</brief_title>
  <official_title>A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, effectiveness, and immunogenicity of
      AA4500 in the treatment of adhesive capsulitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2a, open-label, dose-ranging study of the safety and effectiveness of
      AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for
      treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with
      restricted range of motion in the affected shoulder for at least 3 months but not more than
      12 months. Subjects will be screened for study eligibility within 30 days before injection of
      study drug.

      Approximately 50 adult women and men are to be enrolled in this study. Following screening
      and determination of study eligibility, Assignment to Cohorts 1-4 is sequential. Subjects
      assigned to Cohorts 1 through 4 may receive up to 3 injections of AA4500 according to cohort
      assignment. Each injection will be separated by a minimum of 21 days. Subjects assigned to
      Cohort 5 will receive home shoulder exercises only, while subjects assigned to Cohorts 1-4
      will receive AA4500 and home shoulder exercises. Subjects in Cohort 5 will be offered
      physical therapy sessions for a period of 2 months following completion of the study.

      Dosing will range from 0.29 mg to 0.58 mg with varying volumes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 92 in Active Forward Flexion</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Passive Forward Flexion</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Active Abduction</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>AROM measurement using a goniometer to assess abduction in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Passive Abduction</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>PROM measurement using a goniometer to assess abduction in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Active External Rotation</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>AROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Passive External Rotation</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>PROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Active Internal Rotation</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>AROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in Passive Internal Rotation</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>PROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>Composite score ranging from 0-100, with 0 being worst pain and function loss, derived from the sum of the scores from pain subscale (11-point NRS where 0=no pain at all and 10=pain) and function subscale (activity questionnaire where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in ASES Pain Subscale</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant assessment of pain in response to &quot;How bad is the pain in your affected shoulder today?&quot; on an 11-point numerical rating scale (NRS) where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 92 in ASES Function Subscale</measure>
    <time_frame>Baseline, Day 92</time_frame>
    <description>Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction With Treatment at Day 92</measure>
    <time_frame>Day 92</time_frame>
    <description>Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Improvement With Treatment at Day 92</measure>
    <time_frame>Day 92</time_frame>
    <description>Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adhesive Capsulitis</condition>
  <condition>Frozen Shoulder</condition>
  <arm_group>
    <arm_group_label>AA4500 0.29 mg/1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg/2 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg/1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg/0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shoulder exercises</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Home shoulder exercises for 64 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500 0.29 mg/1 mL</intervention_name>
    <description>treatment of adhesive capsulitis</description>
    <arm_group_label>AA4500 0.29 mg/1 mL</arm_group_label>
    <other_name>collagenase clostridium histolyticum</other_name>
    <other_name>XIAFLEX</other_name>
    <other_name>XIAPEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500 0.58 mg/2 mL</intervention_name>
    <description>treatment of adhesive capsulitis</description>
    <arm_group_label>AA4500 0.58 mg/2 mL</arm_group_label>
    <other_name>collagenase clostridium histolyticum</other_name>
    <other_name>XIAFLEX</other_name>
    <other_name>XIAPEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500 0.58 mg/1 mL</intervention_name>
    <description>treatment of adhesive capsulitis</description>
    <arm_group_label>AA4500 0.58 mg/1 mL</arm_group_label>
    <other_name>collagenase clostridium histolyticum</other_name>
    <other_name>XIAFLEX</other_name>
    <other_name>XIAPEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500 0.58 mg/0.5 mL</intervention_name>
    <description>treatment of adhesive capsulitis</description>
    <arm_group_label>AA4500 0.58 mg/0.5 mL</arm_group_label>
    <other_name>collagenase clostridium histolyticum</other_name>
    <other_name>XIAFLEX</other_name>
    <other_name>XIAPEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Shoulder exercises</intervention_name>
    <description>Home shoulder exercises, minimum of 3 times per day</description>
    <arm_group_label>AA4500 0.29 mg/1 mL</arm_group_label>
    <arm_group_label>AA4500 0.58 mg/2 mL</arm_group_label>
    <arm_group_label>AA4500 0.58 mg/1 mL</arm_group_label>
    <arm_group_label>AA4500 0.58 mg/0.5 mL</arm_group_label>
    <arm_group_label>Shoulder exercises</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a male or female and be greater than or equal to 18 years of age

          2. If a female of childbearing potential, have a negative urine pregnancy test and be
             using an effective contraception method (ie, abstinence, intrauterine device (IUD),
             hormonal (estrogen/progestin) contraceptives, or barrier control) for at least one
             menstrual cycle prior to study enrollment and for one menstrual cycle following end of
             study, or be surgically sterile

          3. Have unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months
             but not more than 12 months before the screening visit and be in Stage 2 (frozen or
             adhesive stage), as determined by the investigator

          4. Have normal range of motion in the contralateral shoulder, as determined by the
             investigator

          5. Have restricted active range of motion (AROM) in the affected shoulder defined as: a
             deficit of at least 60 degrees in total AROM in the affected shoulder as compared with
             the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in
             AROM in at least one of the following planes as compared with the contralateral
             shoulder:

               -  Forward flexion

               -  Abduction

               -  External rotation with the elbow up to 90 degrees abduction

               -  Internal rotation with the elbow up to 90 degrees abduction

          6. Voluntarily sign and date an informed consent agreement approved by the Institutional
             Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an
             authorization form to allow disclosure of his protected health information (PHI). The
             PHI authorization form and informed consent form may be an integrated form or may be
             separate forms depending on the institution.

          7. Be able to complete and understand the various rating instruments in English.

        Exclusion Criteria:

          1. Is a pregnant or lactating female or female intending to become pregnant during the
             study

          2. Is a male who intends to father a child during the study

          3. Has received treatment for adhesive capsulitis or is planning to receive treatment for
             adhesive capsulitis at any time during the study including but not limited to:

               -  physical therapy or acupuncture within 2 weeks before the first injection of
                  AA4500

               -  intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve
                  blocks; corticosteroids; electroanalgesic and/or thermoanalgesic modalities
                  within 1 month before the screening visit

               -  intra-articular or intrabursal injection(s) of sodium hyaluronate within 3 months
                  before the screening visit

               -  glenohumeral distension arthrography and/or surgical intervention (including
                  shoulder manipulation under anesthesia) at any time

          4. Has any of the following conditions, as determined by the investigator:

               -  Adhesive capsulitis as a result of traumatic injury

               -  Pain in the affected shoulder at rest that is greater than or equal to 4 on the
                  11-point pain scale

               -  Active subacromial impingement in the affected shoulder

               -  Calcified tendonitis in the affected shoulder

               -  Glenohumeral joint arthritis in the affected shoulder

               -  Arthrosis of the affected shoulder

               -  Chondrolysis of the affected shoulder

               -  Subscapularis tendon rupture of the affected shoulder

               -  Other rotator cuff injuries of the affected shoulder

               -  Uncontrolled hypertension

               -  Uncontrolled diabetes

               -  Uncontrolled thyroid disease

               -  History of thrombosis or post-thrombosis syndrome

               -  Physical impairment that would preclude performing the protocol defined exercises

               -  Active infection in area to be treated

               -  Clinically significant neurological disease

               -  Coagulation disorder, using anticoagulant (except for less than or equal to 150
                  mg aspirin) within 7 days prior to each injection day

               -  Known active hepatitis B or C (history of hepatitis A permitted)

               -  Other significant medical condition (eg, morbid obesity, cervical disc disease),
                  which in the investigator's opinion would make the subject unsuitable for
                  enrollment in the study

          5. Is unwilling or unable to cooperate with the requirements of the study including
             completion of all scheduled study visits.

          6. Has received oral or intravenous steroids for any reason within 3 weeks before the
             screening visit

          7. Has received an investigational drug or treatment within 30 days before the first dose
             of study drug.

          8. Has a known systemic allergy to collagenase or any other excipient of AA4500 or any
             other procedural medication.

          9. Has, at any time, received collagenase for the treatment of adhesive capsulitis.

         10. Is unable to undergo an x-ray or MRI (contraindication) evaluation of the affected
             shoulder.

         11. Is planning to be treated with commercial Xiaflex at any time during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil H Shusterman, MD FACP</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Orthopaedic Center - Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoArkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CORE Orthopaedic Medical Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triwest Research Associates</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Clinical Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Orthopedic Associates</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Hand to Shoulder Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David R. Mandel, MD, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Orthopedic Associates, Inc.</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research, LLC</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basin Orthopedic Surgical Specialists</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2017</results_first_posted>
  <disposition_first_submitted>March 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 3, 2015</disposition_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AA4500 0.29 mg/1 mL</title>
          <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="P2">
          <title>AA4500 0.58 mg/2 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="P3">
          <title>AA4500 0.58 mg/1 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="P4">
          <title>AA4500 0.58 mg/0.5 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="P5">
          <title>Shoulder Exercises Only</title>
          <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AA4500 0.29 mg/1 mL</title>
          <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="B2">
          <title>AA4500 0.58 mg/2 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="B3">
          <title>AA4500 0.58 mg/1 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="B4">
          <title>AA4500 0.58 mg/0.5 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="B5">
          <title>Shoulder Exercises Only</title>
          <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="4.93"/>
                    <measurement group_id="B2" value="54.1" spread="8.81"/>
                    <measurement group_id="B3" value="58.4" spread="8.97"/>
                    <measurement group_id="B4" value="53.2" spread="5.71"/>
                    <measurement group_id="B5" value="55.1" spread="7.02"/>
                    <measurement group_id="B6" value="54.0" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 92 in Active Forward Flexion</title>
        <description>Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Active Forward Flexion</title>
          <description>Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="13.83"/>
                    <measurement group_id="O2" value="37.5" spread="22.89"/>
                    <measurement group_id="O3" value="42.9" spread="30.64"/>
                    <measurement group_id="O4" value="23.8" spread="41.97"/>
                    <measurement group_id="O5" value="12.0" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Passive Forward Flexion</title>
        <description>Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Passive Forward Flexion</title>
          <description>Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="11.92"/>
                    <measurement group_id="O2" value="39.1" spread="22.13"/>
                    <measurement group_id="O3" value="46.2" spread="20.35"/>
                    <measurement group_id="O4" value="10.5" spread="23.96"/>
                    <measurement group_id="O5" value="12.0" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Active Abduction</title>
        <description>AROM measurement using a goniometer to assess abduction in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Active Abduction</title>
          <description>AROM measurement using a goniometer to assess abduction in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="15.81"/>
                    <measurement group_id="O2" value="36.0" spread="32.94"/>
                    <measurement group_id="O3" value="53.7" spread="27.59"/>
                    <measurement group_id="O4" value="35.8" spread="41.02"/>
                    <measurement group_id="O5" value="16.7" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Passive Abduction</title>
        <description>PROM measurement using a goniometer to assess abduction in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Passive Abduction</title>
          <description>PROM measurement using a goniometer to assess abduction in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="15.69"/>
                    <measurement group_id="O2" value="44.8" spread="34.69"/>
                    <measurement group_id="O3" value="56.1" spread="30.05"/>
                    <measurement group_id="O4" value="18.0" spread="40.87"/>
                    <measurement group_id="O5" value="24.3" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Active External Rotation</title>
        <description>AROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Active External Rotation</title>
          <description>AROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="13.39"/>
                    <measurement group_id="O2" value="19.7" spread="27.49"/>
                    <measurement group_id="O3" value="16.6" spread="16.79"/>
                    <measurement group_id="O4" value="7.4" spread="29.15"/>
                    <measurement group_id="O5" value="6.0" spread="27.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Passive External Rotation</title>
        <description>PROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Passive External Rotation</title>
          <description>PROM measurement using a goniometer to assess external rotation in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="9.64"/>
                    <measurement group_id="O2" value="19.3" spread="24.57"/>
                    <measurement group_id="O3" value="40.9" spread="33.71"/>
                    <measurement group_id="O4" value="9.1" spread="29.32"/>
                    <measurement group_id="O5" value="10.7" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Active Internal Rotation</title>
        <description>AROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Active Internal Rotation</title>
          <description>AROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="14.12"/>
                    <measurement group_id="O2" value="13.0" spread="20.85"/>
                    <measurement group_id="O3" value="9.5" spread="26.87"/>
                    <measurement group_id="O4" value="17.4" spread="24.43"/>
                    <measurement group_id="O5" value="1.2" spread="20.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in Passive Internal Rotation</title>
        <description>PROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in Passive Internal Rotation</title>
          <description>PROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="16.87"/>
                    <measurement group_id="O2" value="19.8" spread="21.70"/>
                    <measurement group_id="O3" value="13.1" spread="23.38"/>
                    <measurement group_id="O4" value="23.6" spread="18.77"/>
                    <measurement group_id="O5" value="2.9" spread="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score</title>
        <description>Composite score ranging from 0-100, with 0 being worst pain and function loss, derived from the sum of the scores from pain subscale (11-point NRS where 0=no pain at all and 10=pain) and function subscale (activity questionnaire where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score</title>
          <description>Composite score ranging from 0-100, with 0 being worst pain and function loss, derived from the sum of the scores from pain subscale (11-point NRS where 0=no pain at all and 10=pain) and function subscale (activity questionnaire where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="13.17"/>
                    <measurement group_id="O2" value="41.6" spread="18.99"/>
                    <measurement group_id="O3" value="35.9" spread="24.33"/>
                    <measurement group_id="O4" value="19.3" spread="24.29"/>
                    <measurement group_id="O5" value="9.9" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in ASES Pain Subscale</title>
        <description>Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant assessment of pain in response to &quot;How bad is the pain in your affected shoulder today?&quot; on an 11-point numerical rating scale (NRS) where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in ASES Pain Subscale</title>
          <description>Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant assessment of pain in response to &quot;How bad is the pain in your affected shoulder today?&quot; on an 11-point numerical rating scale (NRS) where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="11.06"/>
                    <measurement group_id="O2" value="15.5" spread="13.22"/>
                    <measurement group_id="O3" value="15.5" spread="14.99"/>
                    <measurement group_id="O4" value="8.0" spread="12.52"/>
                    <measurement group_id="O5" value="1.5" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 92 in ASES Function Subscale</title>
        <description>Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
        <time_frame>Baseline, Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 92 in ASES Function Subscale</title>
          <description>Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="8.72"/>
                    <measurement group_id="O2" value="26.0" spread="10.98"/>
                    <measurement group_id="O3" value="19.2" spread="12.36"/>
                    <measurement group_id="O4" value="11.3" spread="13.53"/>
                    <measurement group_id="O5" value="8.4" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction With Treatment at Day 92</title>
        <description>Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.</description>
        <time_frame>Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Treatment at Day 92</title>
          <description>Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied nor dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite dissatisfies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Improvement With Treatment at Day 92</title>
        <description>Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.</description>
        <time_frame>Day 92</time_frame>
        <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.29 mg/1 mL</title>
            <description>Up to 3 injections of collagenase clostridium histolyticum (AA4500) 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>AA4500 0.58 mg/2 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O3">
            <title>AA4500 0.58 mg/1 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O4">
            <title>AA4500 0.58 mg/0.5 mL</title>
            <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
          <group group_id="O5">
            <title>Shoulder Exercises Only</title>
            <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Improvement With Treatment at Day 92</title>
          <description>Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.</description>
          <population>All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>129 days (up to 30 day screening period and 92±7 day study period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AA4500 0.29 mg/1 mL</title>
          <description>Up to 3 injections of AA4500 0.29 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="E2">
          <title>AA4500 0.58 mg/2 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/2 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="E3">
          <title>AA4500 0.58 mg/1 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/1 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="E4">
          <title>AA4500 0.58 mg/0.5 mL</title>
          <description>Up to 3 injections of AA4500 0.58 mg/0.5 mL
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
        <group group_id="E5">
          <title>Shoulder Exercises Only</title>
          <description>Home shoulder exercises for 64 days
Shoulder exercises: Home shoulder exercises, minimum of 3 times per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="14" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

